Tumor Immunotherapy
Lysogenic Cycle of Bacteriophages
Bacterial Transformation
DNA Bacteriophages
Rous Sarcoma Virus (RSV) and Cancer
Microorganisms in Medicine and Therapeutics
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 22, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Jianjiang Chen1, Yanbin Liu2, Yumin Wu2
1State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning, Guangxi, 530021, China; National Center for International Research of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China; Guangxi Key Laboratory of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, China; Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China; Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, Guangxi, 530021, China; Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning, Guangxi, 530021, China.
Engineered oncolytic bacteria, using synthetic biology, offer precise cancer therapy by controlling therapeutic payloads. These programmable living therapeutics enhance tumor targeting and safety for cancer treatment.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: